Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Indian (NIFTY) Pharma Industry Analysis

UpdatedJun 28, 2026
DataAggregated Company Financials
Companies183
  • 7D2.0%
  • 3M13.6%
  • 1Y10.6%
  • YTD12.3%

In the last week, the Pharma industry is up 2.0%, with Cipla leading the way with a 6.5% gain. This means that the industry has gained 11% over the past year. Earnings are forecast to grow by 16% annually.

Industry Valuation and Performance

Has the Indian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 29 Jun 2026₹22.9t₹4.5t₹643.1b29.7x35.7x5.1x
Wed, 27 May 2026₹22.4t₹4.5t₹640.1b30.4x35x5x
Fri, 24 Apr 2026₹20.8t₹4.3t₹621.0b29.3x33.5x4.8x
Sun, 22 Mar 2026₹20.1t₹4.3t₹621.2b25.6x32.3x4.6x
Tue, 17 Feb 2026₹20.1t₹4.3t₹621.0b26.5x32.3x4.6x
Thu, 15 Jan 2026₹20.2t₹4.2t₹613.3b28.4x32.9x4.8x
Sat, 13 Dec 2025₹20.6t₹4.2t₹614.4b28.1x33.5x4.9x
Mon, 10 Nov 2025₹20.1t₹4.2t₹608.0b30.6x33x4.8x
Wed, 08 Oct 2025₹20.1t₹4.1t₹588.1b30.3x34.1x4.9x
Fri, 05 Sep 2025₹20.2t₹4.1t₹589.3b30x34.3x5x
Sun, 03 Aug 2025₹20.3t₹4.0t₹587.6b31.7x34.6x5x
Tue, 01 Jul 2025₹20.4t₹4.0t₹595.4b33.6x34.3x5.1x
Thu, 29 May 2025₹19.8t₹4.0t₹592.0b32.9x33.5x5x
Sat, 26 Apr 2025₹19.5t₹3.9t₹560.8b30x34.9x5x
Mon, 24 Mar 2025₹19.8t₹3.9t₹559.4b30.3x35.4x5.1x
Wed, 19 Feb 2025₹18.9t₹3.9t₹560.1b28.5x33.8x4.9x
Fri, 17 Jan 2025₹20.0t₹3.8t₹527.1b32.5x38x5.2x
Sun, 15 Dec 2024₹20.6t₹3.8t₹526.7b35.2x39x5.4x
Tue, 12 Nov 2024₹20.6t₹3.8t₹513.1b37.1x40.2x5.4x
Thu, 10 Oct 2024₹21.8t₹3.7t₹492.6b40.8x44.3x5.9x
Sat, 07 Sep 2024₹21.3t₹3.7t₹492.4b41.9x43.3x5.7x
Mon, 05 Aug 2024₹19.9t₹3.7t₹472.1b37.7x42.2x5.4x
Wed, 03 Jul 2024₹17.7t₹3.6t₹448.3b33.7x39.4x4.9x
Fri, 31 May 2024₹16.9t₹3.6t₹452.1b32.5x37.3x4.7x
Sun, 28 Apr 2024₹17.0t₹3.5t₹418.1b34.6x40.6x4.9x
Tue, 26 Mar 2024₹16.8t₹3.5t₹418.7b32.4x40.1x4.8x
Thu, 22 Feb 2024₹17.0t₹3.5t₹418.6b34.2x40.6x4.9x
Sat, 20 Jan 2024₹15.7t₹3.4t₹395.3b35x39.8x4.6x
Mon, 18 Dec 2023₹14.3t₹3.4t₹395.2b32.2x36.2x4.2x
Wed, 15 Nov 2023₹13.7t₹3.4t₹394.5b31.3x34.7x4.1x
Fri, 13 Oct 2023₹13.1t₹3.3t₹369.9b30x35.4x4x
Sun, 10 Sep 2023₹13.1t₹3.3t₹369.5b30.3x35.5x4x
Tue, 08 Aug 2023₹13.1t₹3.2t₹356.8b29.5x36.7x4.1x
Thu, 06 Jul 2023₹11.7t₹3.2t₹342.4b26.6x34.2x3.7x
Price to Earnings Ratio

34.2x


Total Market Cap: ₹11.7tTotal Earnings: ₹342.4bTotal Revenue: ₹3.2tTotal Market Cap vs Earnings and Revenue0%0%0%
Indian Pharma Industry Price to Earnings3Y Average 36.5x202420252026
Current Industry PE
  • Investors are relatively neutral on the Indian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 36.5x.
  • The industry is trading close to its 3-year average PS ratio of 4.8x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 23% per year over the last three years.
  • Revenues for these companies have grown 12% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Indian Healthcare industry?

IN Market-0.48%
Healthcare1.51%
Pharma2.05%
Pharma2.05%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
500124 Dr. Reddy's Laboratories₹1.35k4.6%
+₹49.1b		5.2%PE26.2x
AUROPHARMA Aurobindo Pharma₹1.56k3.8%
+₹33.0b		38.7%PE25.5x
AETHER Aether Industries₹1.33k14.0%
+₹21.6b		73.1%PE80.1x
GLAND Gland Pharma₹2.31k5.9%
+₹21.1b		26.2%PE37.1x
500420 Torrent Pharmaceuticals₹4.52k1.4%
+₹20.4b		32.5%PE70.7x

Latest News

SANOFICONR
₹4,618.10
Sanofi Consumer Healthcare India
7D
-4.0%
1Y
-7.9%
CIPLA
₹1,440.10
Cipla
7D
1.7%
1Y
-4.4%
AUROPHARMA
₹1,555.20
Aurobindo Pharma
7D
3.8%
1Y
38.7%
500124
₹1,350.00
Dr. Reddy's Laboratories
7D
4.6%
1Y
5.2%
Narrative Update • Jun 25

500124: Lower Profitability Expectations Will Restrain Future Share Price Upside

Analysts have adjusted their price target for Dr. Reddy's Laboratories from ₹1,024 to ₹1,040, reflecting updated views on revenue growth, profit margins and future P/E assumptions in their valuation work. What's in the News Dr. Reddy's Laboratories has scheduled a board meeting for July 22, 2026, to consider the unaudited standalone and consolidated financial results for the quarter ending June 30, 2026.
500420
₹4,518.15
Torrent Pharmaceuticals
7D
1.4%
1Y
32.5%
Narrative Update • Jun 25

500420: Dividend Payouts And Stable Assumptions Will Support A Balanced Outlook

Analysts have kept their fair value estimate for Torrent Pharmaceuticals steady at about ₹4,878.79 per share, citing unchanged assumptions for revenue growth, profit margins, discount rate, and future P/E multiple. What's in the News for Torrent Pharmaceuticals At its AGM on 23 June 2026, Torrent Pharmaceuticals declared a final dividend of ₹9.00 per equity share of face value ₹5.00 for the financial year ended 31 March 2026.
GLAND
₹2,314.80
Gland Pharma
7D
5.9%
1Y
26.2%
Narrative Update • Jun 24

GLAND: US Injectable Approvals And Dividend Will Support Future Rerating

Analysts have kept their ₹2,645 price target on Gland Pharma unchanged, citing relatively steady assumptions around revenue growth, profit margins and future P/E multiples in their updated model. What’s in the News for Gland Pharma The U.S. FDA approved Apotex, Orbicular and Gland Pharma’s Abbreviated New Drug Application for generic Infuvite Pediatric Injection.
GLENMARK
₹2,154.40
Glenmark Pharmaceuticals
7D
-1.7%
1Y
22.8%
Narrative Update • Jun 23

GLENMARK: US Respiratory And Women’s Health launches Will Support Stronger Outlook

Analysts have lifted their price target for Glenmark Pharmaceuticals from ₹2,129.50 to ₹2,496.50, reflecting updated views on revenue growth assumptions, profit margins, and future P/E expectations. What’s in the News for Glenmark Pharmaceuticals Glenmark Pharmaceuticals held an Analyst and Investor Day, giving the market a closer look at its business priorities and the outlook it shared with institutional stakeholders.
COHANCE
₹458.05
Cohance Lifesciences
7D
12.9%
1Y
-51.5%
Narrative Update • Jun 18

COHANCE: Leadership Transition And Incentive Plans Will Support Complex Pharma Expansion

Analysts have kept their price target for Cohance Lifesciences steady at ₹516.78, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margins and future P/E expectations. What’s in the News for Cohance Lifesciences Appointment of Umang Vohra as Group CEO of Cohance Lifesciences, effective May 20, 2026, with the outgoing leader, Mr. Sharma, continuing as an advisor for around nine months to support the transition.
LAURUSLABS
₹1,450.00
Laurus Labs
7D
2.6%
1Y
106.6%
Narrative Update • Jun 18

LAURUSLABS: Dividend Moves And Governance Changes Will Shape Future Stock Appeal

Analysts have raised their fair value estimate for Laurus Labs to ₹1,370 from ₹1,270, reflecting updated assumptions around slightly adjusted growth, lower profit margins and a higher future P/E multiple in their latest models. Analyst Commentary Bullish analysts looking at Laurus Labs are focusing on how updated assumptions flow through to valuation, execution expectations and potential growth drivers.
SPARC
₹224.92
Sun Pharma Advanced Research
7D
-5.5%
1Y
38.5%
CONCORDBIO
₹1,286.10
Concord Biotech
7D
-2.2%
1Y
-29.5%
Narrative Update • Jun 15

CONCORDBIO: Slower Earnings Outlook Will Limit Upside Despite Upcoming Dividend

Analysts have trimmed their price target on Concord Biotech from ₹1,319 to ₹1,196, citing adjusted expectations for revenue growth, profit margins, and the future P/E multiple. What's in the News A board meeting is scheduled for May 29, 2026, at 15:00 IST to review the audited standalone and consolidated financial results for Q4 and the full year ended March 31, 2026, along with the related audit reports.
MANKIND
₹2,462.30
Mankind Pharma
7D
-3.0%
1Y
6.1%
Narrative Update • Jun 15

MANKIND: Subsidiary Reshuffle And Higher P/E Assumptions Will Support Re Rating

Analysts have raised the price target for Mankind Pharma slightly to ₹3,100 from ₹3,085.68, reflecting updated assumptions regarding a higher future P/E multiple, as well as adjusted expectations for revenue growth, profit margins, and the discount rate. What's in the News Board meeting on May 19, 2026 to review standalone and consolidated audited financial results for the quarter and year ended March 31, 2026, consider realignment of security cover for existing non convertible debentures after redemption of ₹12,50,00,00,000 of NCDs on April 16, 2026, review management changes, and evaluate additional investment in subsidiaries.
AETHER
₹1,325.10
Aether Industries
7D
14.0%
1Y
73.1%
Narrative Update • Jun 15

AETHER: Board Review And Leadership Appointment Will Support A Measured Outlook

Analysts have kept the price target for Aether Industries steady at ₹1,226.80, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margin and future P/E in their latest update. What's in the News Aether Industries has scheduled a Board Meeting on May 15, 2026, at 14:22 Indian Standard Time.
532482
₹763.55
Granules India
7D
-2.8%
1Y
53.5%
Narrative Update • Jun 11

532482: Fair Outlook Will Hinge On Upcoming FY 2025-26 Results And Dividend

Analysts have nudged their price target for Granules India higher to about ₹786 from roughly ₹698, citing updated assumptions that reflect adjusted revenue growth, profit margin expectations, discount rate inputs, and a revised future P/E multiple. What's in the News A board meeting is scheduled for April 29, 2026, to consider and approve audited financial results for the fourth quarter and full year ended March 31, 2026, and to consider a final dividend for FY 2025-26, if any.
WOCKPHARMA
₹1,965.20
Wockhardt
7D
-2.4%
1Y
14.7%
500488
₹25,591.00
Abbott India
7D
-1.9%
1Y
-28.2%